AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie long-Term Debt and Finance Lease Obligations, Noncurrent ($M) ($M)
Form 10-Q / 10-K Consolidated Balance Sheets & Debt Note
Latest, Q2 2026
62,481
Period ended Jun 30, 2026
Change on a year earlier
-0.8%
62,959 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
39
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Long-Term Debt and Finance Lease Obligations, Noncurrent ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 62,481 | -0.8% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 64,532 | 0.0% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 58,941 | -2.3% | Form 10-Q (filed 2026-08-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 62,971 | +7.6% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 62,959 | +8.5% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 64,527 | +1.1% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 60,340 | +15.6% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 58,509 | +5.2% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 58,048 | +4.0% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 63,805 | +7.6% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 52,194 | -11.7% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 55,631 | -7.9% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 55,812 | -8.5% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 59,292 | -6.7% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 59,135 | -7.9% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2022 | Sep 30, 2022 | 60,399 | -18.4% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 61,002 | -17.8% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 63,522 | -14.4% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 64,189 | -17.2% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2021 | Sep 30, 2021 | 74,049 | -10.0% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 74,237 | -9.5% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 74,183 | +17.2% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 77,554 | +23.2% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2020 | Sep 30, 2020 | 82,282 | +148.4% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 82,061 | +159.5% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 63,284 | +80.5% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 62,975 | +79.9% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2019 | Sep 30, 2019 | 33,126 | -9.2% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 31,619 | +3.4% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 35,066 | +13.5% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 35,002 | +13.1% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2018 | Sep 30, 2018 | 36,487 | +7.4% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2018 | Jun 30, 2018 | 30,579 | -9.6% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 30,906 | -15.4% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2017 | Dec 31, 2017 | 30,953 | -15.1% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 33,974 | -8.9% | 10-Q FY2017 (XBRL) ↗ |
| Q2 2017 | Jun 30, 2017 | 33,817 | -9.4% | 10-Q FY2017 (XBRL) ↗ |
| Q1 2017 | Mar 31, 2017 | 36,526 | +23.9% | 10-Q FY2017 (XBRL) ↗ |
| Q4 2016 | Dec 31, 2016 | 36,440 | +24.6% | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2016 | Sep 30, 2016 | 37,284 | +18.9% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 37,328 | +37.7% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 29,490 | +176.0% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 29,240 | – | Form 10-K (filed 2017-02-17) ↗ |
| Q3 2015 | Sep 30, 2015 | 31,359 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 27,116 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 10,683 | – | 10-Q FY2015 (XBRL) ↗ |
Breakdown
What makes up long-term debt and finance lease obligations, noncurrent ($m)
- Current Portion of Long-Term Debt and Finance Leases ($M)8,341 · Q2 2026
- Short-Term Borrowings ($M)0 · Q2 2026
- Cash Paid for Interest [annual] ($M)–
- Long-Term Debt Maturities — Year 1 ($M)–
- Long-Term Debt Maturities — Year 2 ($M)–
- Long-Term Debt Maturities — Year 3 ($M)–
- Long-Term Debt Maturities — Year 4 ($M)–
- Long-Term Debt Maturities — Year 5 ($M)–
- Long-Term Debt Maturities — After Year 5 ($M)–
Cite this data
StockData. (2026). AbbVie Long-Term Debt and Finance Lease Obligations, Noncurrent ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/debt_lt_nc
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.